JPWO2021183359A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021183359A5 JPWO2021183359A5 JP2022554815A JP2022554815A JPWO2021183359A5 JP WO2021183359 A5 JPWO2021183359 A5 JP WO2021183359A5 JP 2022554815 A JP2022554815 A JP 2022554815A JP 2022554815 A JP2022554815 A JP 2022554815A JP WO2021183359 A5 JPWO2021183359 A5 JP WO2021183359A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- variable region
- binding fragment
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 55
- 102000036639 antigens Human genes 0.000 claims description 55
- 108091007433 antigens Proteins 0.000 claims description 55
- 239000012634 fragment Substances 0.000 claims description 55
- 230000027455 binding Effects 0.000 claims description 51
- 239000008194 pharmaceutical composition Substances 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 28
- 208000025721 COVID-19 Diseases 0.000 claims description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 229940127121 immunoconjugate Drugs 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000009870 specific binding Effects 0.000 claims description 9
- 229960005486 vaccine Drugs 0.000 claims description 9
- 241001678559 COVID-19 virus Species 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 208000037750 SARS-CoV-2-related disease Diseases 0.000 claims description 6
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 229940068968 polysorbate 80 Drugs 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 239000002254 cytotoxic agent Substances 0.000 claims description 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 3
- 239000000032 diagnostic agent Substances 0.000 claims description 3
- 229940039227 diagnostic agent Drugs 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 2
- 241000711573 Coronaviridae Species 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- 208000037847 SARS-CoV-2-infection Diseases 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000010998 test method Methods 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 229930182474 N-glycoside Natural products 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062987313P | 2020-03-09 | 2020-03-09 | |
| US62/987,313 | 2020-03-09 | ||
| US202063010999P | 2020-04-16 | 2020-04-16 | |
| US63/010,999 | 2020-04-16 | ||
| US202063030530P | 2020-05-27 | 2020-05-27 | |
| US63/030,530 | 2020-05-27 | ||
| US202063036089P | 2020-06-08 | 2020-06-08 | |
| US63/036,089 | 2020-06-08 | ||
| US202063080351P | 2020-09-18 | 2020-09-18 | |
| US63/080,351 | 2020-09-18 | ||
| US202063085042P | 2020-09-29 | 2020-09-29 | |
| US63/085,042 | 2020-09-29 | ||
| US202063116483P | 2020-11-20 | 2020-11-20 | |
| US63/116,483 | 2020-11-20 | ||
| PCT/US2021/020843 WO2021183359A1 (en) | 2020-03-09 | 2021-03-04 | Anti-coronavirus antibodies and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023517236A JP2023517236A (ja) | 2023-04-24 |
| JP2023517236A5 JP2023517236A5 (https=) | 2024-03-13 |
| JPWO2021183359A5 true JPWO2021183359A5 (https=) | 2024-03-13 |
Family
ID=73835506
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554810A Pending JP2023517234A (ja) | 2020-03-09 | 2020-12-09 | 抗コロナウイルス抗体および使用の方法 |
| JP2022554815A Pending JP2023517236A (ja) | 2020-03-09 | 2021-03-04 | 抗コロナウイルス抗体および使用の方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554810A Pending JP2023517234A (ja) | 2020-03-09 | 2020-12-09 | 抗コロナウイルス抗体および使用の方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US20210292393A1 (https=) |
| EP (2) | EP3878862A3 (https=) |
| JP (2) | JP2023517234A (https=) |
| KR (2) | KR102535195B1 (https=) |
| CN (2) | CN116096742A (https=) |
| AU (2) | AU2020435452A1 (https=) |
| BR (2) | BR112022017986A2 (https=) |
| CA (2) | CA3171237A1 (https=) |
| GB (1) | GB2593023A (https=) |
| IL (2) | IL296224A (https=) |
| MA (1) | MA52390A (https=) |
| MX (2) | MX2022011142A (https=) |
| TW (2) | TWI782366B (https=) |
| WO (2) | WO2021183195A1 (https=) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016187356A1 (en) * | 2015-05-18 | 2016-11-24 | Agensys, Inc. | Antibodies that bind to axl proteins |
| WO2016187354A1 (en) * | 2015-05-18 | 2016-11-24 | Agensys, Inc. | Antibodies that bind to axl proteins |
| US20180128545A1 (en) | 2016-11-08 | 2018-05-10 | Berry Metal Company | Modular furnace cooling wall |
| US12384811B2 (en) | 2019-04-05 | 2025-08-12 | Academia Sinica | Sialidase-resistant saccharide and method of making and using the same |
| TWI789711B (zh) * | 2020-02-24 | 2023-01-11 | 中國科學院微生物研究所 | 新型冠狀病毒的人源單克隆抗體及其應用 |
| FI4045533T3 (fi) | 2020-03-26 | 2024-02-02 | Univ Vanderbilt | Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2) |
| CR20220552A (es) | 2020-04-02 | 2023-01-17 | Regeneron Pharma | Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno |
| KR20230038416A (ko) | 2020-05-08 | 2023-03-20 | 아카데미아 시니카 | 키메릭 인플루엔자 백신 |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| AU2021275361A1 (en) * | 2020-05-17 | 2023-01-19 | Astrazeneca Uk Limited | SARS-CoV-2 antibodies and methods of selecting and using the same |
| CA3181026A1 (en) | 2020-06-03 | 2021-12-09 | Samit GANGULY | Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies |
| US20220003779A1 (en) * | 2020-07-03 | 2022-01-06 | The Research Foundation For The State University Of New York | Methods for qualitative and quantitative analysis of a plurality of biomarkers |
| EP4182687A4 (en) * | 2020-07-20 | 2024-09-11 | Bio-Rad Laboratories, Inc. | IMMUNOASSAY FOR SARS-COV-2 NEUTRALISING ANTIBODIES AND MATERIALS THEREFOR |
| WO2022035918A1 (en) * | 2020-08-11 | 2022-02-17 | Eli Lilly And Company | Anti-sars-cov-2 antibodies |
| AR123688A1 (es) * | 2020-10-02 | 2023-01-04 | Lilly Co Eli | Métodos para reducir el contenido de proteínas de célula huésped en procesos de purificación de proteínas |
| US11440952B2 (en) | 2020-10-16 | 2022-09-13 | Invisishield Technologies Ltd. | Compositions for preventing or treating viral and other microbial infections |
| WO2022162587A1 (en) * | 2021-01-27 | 2022-08-04 | Centre Hospitalier Universitaire Vaudois (C.H.U.V.) | Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection |
| CN115141270A (zh) * | 2021-03-29 | 2022-10-04 | 深圳市康麦生物技术有限公司 | 特异性结合新型冠状病毒的抗体 |
| AU2022257113B2 (en) | 2021-04-12 | 2024-07-18 | Academia Sinica | Improved coronavirus vaccine |
| CN113461810B (zh) * | 2021-05-17 | 2021-12-28 | 深圳市福田区格物智康病原研究所 | 一种抗新型冠状病毒刺突蛋白的全人源单克隆抗体及其应用 |
| CA3221441A1 (en) * | 2021-06-08 | 2022-12-15 | Yu Tang | 2019 novel coronavirus antibody-containing pharmaceutical formulations |
| WO2022263638A1 (en) * | 2021-06-17 | 2022-12-22 | Centre Hospitalier Universitaire Vaudois (C.H.U.V.) | Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection |
| WO2023285620A2 (en) * | 2021-07-14 | 2023-01-19 | Alchemab Therapeutics Ltd. | Compositions and methods for targeting viral proteins |
| IL310012A (en) | 2021-07-14 | 2024-03-01 | Regeneron Pharma | Antibodies against SARS-COV-2 spike glycoprotein and antigen-binding fragments |
| US12600764B2 (en) * | 2021-08-27 | 2026-04-14 | International Business Machines Corporation | Antigen-binding proteins targeting coronavirus (COV) variants |
| CN113735969B (zh) * | 2021-09-20 | 2023-05-12 | 中国人民解放军军事科学院军事医学研究院 | 一种全人源抗新冠病毒广谱高中和活性单克隆抗体及应用 |
| TW202334429A (zh) * | 2021-10-01 | 2023-09-01 | 中央研究院 | Sars-cov-2棘蛋白特異性抗體及其用途 |
| US20240400653A1 (en) * | 2021-10-07 | 2024-12-05 | Seqirus Pty Ltd | Anti-sars-cov-2 antibodies and uses thereof i |
| WO2023059900A2 (en) * | 2021-10-08 | 2023-04-13 | Invivyd, Inc. | Pharmaceutical formulations comprising anti-coronavirus s protein antibodies and uses thereof |
| WO2023070051A1 (en) * | 2021-10-22 | 2023-04-27 | Atreca, Inc. | Antibodies to coronavirus sars-cov-2 |
| WO2023076419A2 (en) * | 2021-10-27 | 2023-05-04 | Twist Bioscience Corporation | Sars-cov-2 antibodies and methods of use |
| WO2023079137A1 (en) * | 2021-11-05 | 2023-05-11 | Katholieke Universiteit Leuven | Neutralizing anti-sars-cov-2 human antibodies |
| US20250034234A1 (en) * | 2021-11-09 | 2025-01-30 | Rhode Island Hospital | Predicting covid-19 antibodies among survivors with deep rna sequencing |
| EP4430070A1 (en) * | 2021-11-12 | 2024-09-18 | RQ Biotechnology Limited | Compositions |
| MX2024005999A (es) * | 2021-11-19 | 2024-05-30 | Ap Biosciences Inc | Anticuerpos bispecificos dirigidos a cd137 y usos de los mismos para la inmunoterapia anticancer. |
| EP4183800A1 (en) * | 2021-11-19 | 2023-05-24 | Medizinische Hochschule Hannover | Novel sars-cov-2 neutralizing antibodies |
| CN116217711A (zh) * | 2021-12-03 | 2023-06-06 | 广东菲鹏生物有限公司 | 一种SARS-CoV-2检测方法和试剂盒 |
| KR102793620B1 (ko) | 2021-12-09 | 2025-04-09 | 한국화학연구원 | 사스-코로나바이러스-2 뉴클레오캡시드 단백질에 대한 단클론 항체 및 이의 용도 |
| WO2023133338A2 (en) * | 2022-01-10 | 2023-07-13 | University Of Pittsburgh – Of The Commonwealth System Of Higher Education | Molecules that bind to neutrophil elastase polypeptides |
| CN119421953A (zh) | 2022-01-28 | 2025-02-11 | 株式会社伊贝克 | 具有突变株交叉性的抗SARS－CoV－2人中和抗体及其抗原结合片段 |
| WO2023159061A2 (en) * | 2022-02-15 | 2023-08-24 | Board Of Regents, The University Of Texas System | Human monoclonal antibodies targeting the s2 subunit of the sars-cov-2 spike protein |
| TW202342510A (zh) | 2022-02-18 | 2023-11-01 | 英商Ｒｑ生物科技有限公司 | 抗體 |
| CN119110809A (zh) | 2022-02-23 | 2024-12-10 | Xencor股份有限公司 | 抗CD28 x抗PSMA抗体 |
| WO2023159316A1 (en) * | 2022-02-28 | 2023-08-31 | Immune Biosolutions Inc. | Formulation of anti-sars-cov-2 neutralizing antibodies and uses thereof |
| WO2023168195A2 (en) * | 2022-03-04 | 2023-09-07 | The Scripps Research Institute | Human broadly neutralizing antibodies against betacoronaviruses |
| WO2023178182A1 (en) * | 2022-03-16 | 2023-09-21 | 10X Genomics, Inc. | Compositions and methods for detection and treatment of coronavirus infection |
| CN114349855B (zh) * | 2022-03-18 | 2022-06-28 | 百斯医学诊断科技(北京)有限公司 | 新型冠状病毒Delta突变株特异性抗体及其应用 |
| WO2023183848A2 (en) * | 2022-03-25 | 2023-09-28 | The Rockefeller University | Anti-sars-cov-2 antibodies and methods of use thereof |
| EP4505179A2 (en) * | 2022-04-01 | 2025-02-12 | Invivyd, Inc. | Sars-cov2 antibodies and uses thereof |
| CN114656555B (zh) * | 2022-04-08 | 2024-03-19 | 广州医科大学附属第一医院（广州呼吸中心） | 抗SARS-CoV-2病毒的中和抗体及其制备方法和应用 |
| WO2023201306A1 (en) | 2022-04-14 | 2023-10-19 | Invisishield Technologies Ltd. | Compositions for preventing or treating influenza infections |
| CA3256035A1 (en) | 2022-04-14 | 2023-10-19 | Invisishield Technologies Ltd. | COMPOSITIONS FOR PREVENTING OR TREATMENT OF CORONAVIRUS INFECTIONS |
| TW202409073A (zh) * | 2022-07-26 | 2024-03-01 | 圓祥生技股份有限公司 | SARS-CoV-2抗體及雙特異性抗體 |
| CN116143910B (zh) * | 2022-10-12 | 2026-03-24 | 水木未来(北京)科技有限公司 | 靶向SARS-CoV-2刺突蛋白的纳米抗体及其应用 |
| KR20250122456A (ko) * | 2022-11-01 | 2025-08-13 | 프로비던스 헬스 앤드 서비시즈 - 오레곤 | Fas 리간드에 특이적인 단일클론 항체 및 이의 용도 |
| EP4638490A1 (en) | 2022-12-21 | 2025-10-29 | National University of Singapore | Sars-cov-2 spike protein-binding molecules |
| WO2024187177A2 (en) * | 2023-03-09 | 2024-09-12 | The Johns Hopkins University | Recombinant antibody for the treatment of extracellular dna overload |
| CN121240887A (zh) | 2023-04-08 | 2025-12-30 | 磐石医药生技股份有限公司 | 通过聚合物囊泡进行靶向递送的方法和组合物 |
| US12508235B2 (en) | 2023-04-08 | 2025-12-30 | Rock Biomedical, Inc. | Methods and compositions for dendritic cell targeting nano-delivery |
| WO2024238734A2 (en) | 2023-05-17 | 2024-11-21 | Rock Biomedical Inc. | Mgat1 deficient cells and uses thereof |
| WO2025222126A1 (en) * | 2024-04-19 | 2025-10-23 | Vanderbilt University | Var2csa antibodies and methods of use thereof |
| US20260061066A1 (en) * | 2024-06-03 | 2026-03-05 | Uct Bioscience Co., Ltd. | Anti-grp78 antibody, immunoconjugate and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6323840B1 (en) | 1999-09-17 | 2001-11-27 | Cts Corporation | Surface-mount pointing device |
| US20040191260A1 (en) * | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| US7892563B2 (en) | 2003-05-20 | 2011-02-22 | Wyeth Holdings Corporation | Methods for treatment of severe acute respiratory syndrome (SARS) |
| CA2531684C (en) * | 2003-07-22 | 2014-03-11 | Crucell Holland B.V. | Binding molecules against sars-coronavirus and uses thereof |
| EP1644414B1 (en) | 2003-07-22 | 2015-01-14 | Crucell Holland B.V. | Binding molecules against sars-coronavirus and uses thereof |
| EP1812067B1 (en) | 2004-11-11 | 2012-03-21 | Crucell Holland B.V. | Compositions against sars-coronavirus and uses thereof |
| MX2007009512A (es) | 2005-02-08 | 2008-02-21 | New York Blood Ct Inc | Neutralizacion de anticuerpos monoclonales contra coronavirus asociado con sindrome respiratorio agudo severo. |
| WO2015080973A1 (en) * | 2013-11-26 | 2015-06-04 | Baylor College Of Medicine | A novel sars immunogenic composition |
| JO3701B1 (ar) * | 2014-05-23 | 2021-01-31 | Regeneron Pharma | مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي |
| AU2016243026B2 (en) * | 2015-04-03 | 2022-03-31 | Eureka Therapeutics, Inc. | Constructs targeting AFP peptide/MHC complexes and uses thereof |
| EP3892297A1 (en) | 2020-04-09 | 2021-10-13 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Peptides and combinations of peptides for use in immunotherapy against an infection by sars-cov-2 (covid-19) |
| CN111592595B (zh) * | 2020-04-27 | 2021-02-19 | 南京医科大学 | 抗新型冠状病毒SARS-Cov-2的中和性抗体及其应用 |
| CN112300375B (zh) * | 2020-11-06 | 2022-10-25 | 江苏三木化工股份有限公司 | 一种水性光固化环氧丙烯酸树脂的制备方法 |
-
2020
- 2020-12-09 BR BR112022017986A patent/BR112022017986A2/pt unknown
- 2020-12-09 AU AU2020435452A patent/AU2020435452A1/en not_active Abandoned
- 2020-12-09 CA CA3171237A patent/CA3171237A1/en active Pending
- 2020-12-09 CN CN202080100619.3A patent/CN116096742A/zh active Pending
- 2020-12-09 WO PCT/US2020/063991 patent/WO2021183195A1/en not_active Ceased
- 2020-12-09 IL IL296224A patent/IL296224A/en unknown
- 2020-12-09 MX MX2022011142A patent/MX2022011142A/es unknown
- 2020-12-09 JP JP2022554810A patent/JP2023517234A/ja active Pending
- 2020-12-09 US US17/116,588 patent/US20210292393A1/en not_active Abandoned
- 2020-12-14 MA MA052390A patent/MA52390A/fr unknown
- 2020-12-14 TW TW109144053A patent/TWI782366B/zh active
- 2020-12-14 GB GB2019709.1A patent/GB2593023A/en not_active Withdrawn
- 2020-12-14 KR KR1020200174502A patent/KR102535195B1/ko active Active
- 2020-12-14 EP EP20213900.2A patent/EP3878862A3/en active Pending
-
2021
- 2021-03-04 EP EP21719305.1A patent/EP4118110A1/en not_active Withdrawn
- 2021-03-04 WO PCT/US2021/020843 patent/WO2021183359A1/en not_active Ceased
- 2021-03-04 IL IL296333A patent/IL296333A/en unknown
- 2021-03-04 CA CA3171139A patent/CA3171139A1/en active Pending
- 2021-03-04 MX MX2022011141A patent/MX2022011141A/es unknown
- 2021-03-04 US US17/192,243 patent/US20220356229A1/en not_active Abandoned
- 2021-03-04 KR KR1020227032747A patent/KR20220167273A/ko active Pending
- 2021-03-04 JP JP2022554815A patent/JP2023517236A/ja active Pending
- 2021-03-04 CN CN202180033718.9A patent/CN116096744A/zh active Pending
- 2021-03-04 BR BR112022017930A patent/BR112022017930A2/pt unknown
- 2021-03-04 AU AU2021234242A patent/AU2021234242A1/en not_active Abandoned
- 2021-03-08 TW TW110108164A patent/TWI847020B/zh active
- 2021-06-22 US US17/354,434 patent/US11370828B2/en active Active
- 2021-06-22 US US17/354,476 patent/US11447541B1/en active Active
-
2023
- 2023-03-31 US US18/194,105 patent/US12172038B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021183359A5 (https=) | ||
| EP3129047B1 (en) | Stable formulations for anti-cd19 antibodies and antibody-drug conjugates | |
| US11591406B2 (en) | Treatment for multiple myeloma (MM) | |
| JP2021527640A5 (https=) | ||
| US8617548B2 (en) | Methods of preventing or treating anthrax using anti-anthrax antibodies | |
| EP3360896B1 (en) | Antibody to hepatitis b surface antigen and use thereof | |
| US11110179B2 (en) | Combination of CD33 antibody drug conjugates with chemotherapeutic agents | |
| JP2023537078A (ja) | ＣＯＶＩＤ－１９を治療及び防止するためのＳＡＲＳ－ＣｏＶ－２抗体 | |
| JPWO2019243159A5 (https=) | ||
| WO2017180768A1 (en) | Combinations of cd33 antibody drug conjugates with hypomethylating agents | |
| JPWO2021224499A5 (https=) | ||
| JPWO2022053655A5 (https=) | ||
| CN112996540B (zh) | 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途 | |
| RU2020141137A (ru) | Антитела к коронавирусу и способы применения | |
| CN114127108A (zh) | Il-17拮抗剂治疗自身免疫疾病的方法 | |
| TW202547886A (zh) | 用於治療ｃ１ｓ介導的疾病和病症的組成物、劑量和方法 | |
| EP4334351A1 (en) | Treatment for systemic lupus erythematosus using anti-baffr antibodies | |
| JPWO2022046942A5 (https=) | ||
| HK1247939A1 (en) | Treatment for multiple myeloma (mm) |